Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EDC 8

Drug Profile

EDC 8

Alternative Names: EDC-8

Latest Information Update: 12 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Centrose
  • Class Antineoplastics; Drug conjugates; Glycosides; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Discontinued Inflammation

Most Recent Events

  • 12 Sep 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route) (Centrose Pharma pipeline, September 2023)
  • 12 Sep 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route), prior to September 2023 (Centrose Pharma pipeline, September 2023)
  • 12 Sep 2023 Pharmacodynamics data from the preclinical trial in Acute myeloid leukaemia released by Centrose Pharma, prior to September 2023 (Centrose Pharma pipeline, September 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top